设为首页收藏本站
开启辅助访问
切换到窄版

 找回密码
 注册

QQ登录

只需一步,快速开始

搜索
查看: 746|回复: 0

CD-19嵌合抗原受体修饰的T细胞治疗治疗急慢性淋巴细胞白血病

[复制链接]
发表于 2015-11-15 23:24:54 | 显示全部楼层 |阅读模式
CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia
Abstract
Adoptive cell therapy (ACT) for cancer represents a promising new treatment modality. ACT based on the administration of cytotoxic T cells genetically engineered to express a chimeric antigen receptor (CAR) recognizing CD19 expressed by B cell malignancies has been shown to induce complete lasting responses in patients with chronic lymphocytic leukaemia (CLL) and acute lymphoblastic leukaemia (ALL). So far, eleven clinical trials including 99 CLL and ALL patients treated with CAR T cells targeting CD19 have been published, and the results from these trials are promising with impressive clinical responses in heavily pretreated patients. Thus, CAR T cell therapy has induced complete responses in both CLL and ALL, and surprisingly, current results indicate that patients with ALL are more prone to respond than are CLL patients. Importantly, the majority of CAR cell studies have observed severe therapy-associated toxicities, which needs attention. Herein we review current data and discuss key aspects of this powerful approach to treat and potentially cure B cell malignancies.
CD-19嵌合抗原受体修饰的T细胞治疗治疗急慢性淋巴细胞白血病
摘要:
用过继细胞治疗(ACT)癌症代表着一个具有前景的新治疗方式。以T细胞毒性为基础的,表达识别B淋巴细胞表面CD19CAR的过继细胞治疗已经在慢性淋巴细胞白血病和急性淋巴细胞白血病病人的治疗中显示出了完全持续的疗效。到目前为止,
到目前为止,共有十一个使用靶向CD19CAR-T细胞的临床试验已经发布,包括99CLLALL病人。这些临床实验的结果显示在严重的病人身上展现了很好的临床疗效。因此,CAR-T细胞治疗在CLL病人和ALL病人身上都有完全的疗效。而令人惊讶的是,研究结果表明,ALL病人的治疗更加有效。重要的是,大多数的CAR-T细胞研究已经观察到严重的治疗相关的毒性,需要注意。在这里,我们回顾了目前的数据,并讨论这个强大的治疗和潜在治愈B淋巴细胞白血病的方案的关键因素。

CD19-Chimeric Antigen Receptor T 2015.11.14.pdf

267.96 KB, 下载次数: 351

您需要登录后才可以回帖 登录 | 注册

本版积分规则

QQ|申请友链|小黑屋|手机版|Archiver|生物信息学论坛 ( 蜀ICP备09031721号  

GMT+8, 2017-4-29 11:35 , Processed in 0.111585 second(s), 29 queries .

Powered by Discuz! X3

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表